Press "Enter" to skip to content

Lupin aims to launch new products across geographies this fiscal

"Looking ahead, FY2020 is an exciting year for Lupin as we plan to bring our first biosimilar to market, commercialise our first inhalation product in the US, continue the growth momentum in our US generics business and launch our injectables portfolio," they said in a joint letter to the shareholders.

Original source:

Also Read:   Kids may not be recommended for Covid-19 vaccination initially, U.S. CDC says